CINCINNATI, Jan. 14 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a
leading, global full-service clinical research organization, today announced
the opening of a second office in western India in the city of Ahmedabad,
further expanding its presence in the country and executing on its plans for
continued growth in the Asia/Pacific region. Kendle has operated in New
Delhi, India since 2004 and is targeting additional expansion in India in 2009
to meet customer needs.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )
"Expansion in the Asia/Pacific region, and India in particular, is
essential to our continued success as a top global CRO," said Candace Kendle,
PharmD, Chairman and CEO. "Our increased presence and capacity in the region
will allow us to better meet the needs of our customers who are seeking to
capitalize on India's cost-effective, yet high-quality clinical research
capabilities to develop their compounds. Our expansion into Ahmedabad is
another step in our continued development of a best-in-class infrastructure
throughout Asia."
Kendle's India operations provide customers access to the full spectrum of
early and late stage clinical development services conducted by staff
experienced in running all phases of trials across all therapeutic areas. The
new Ahmedabad office builds on Kendle's already strong presence in New Delhi,
offering increased efficiencies and geographic coverage and providing access
to the talent pool in the western part of the country.
Kendle's expansion in India reflects the growing importance of the country
to the global clinical research market. With more than one billion people, a
growing and improving research infrastructure, an efficient and evolving
regulatory setting, favorable intellectual property laws, a large pool of
medical professionals and established research credentials, India is quickly
becoming a world power in clinical research. Analysts estimate that by 2011
as many as 15 percent of all global trials will be conducted in India.
Kendle's office in Ahmedabad is located at Kendle India Private Limited,
B/901, Safal Pegasus, 100 Feet Road, Near AUDA Garden, Prahalad Nagar,
Ahmedabad - 380051, Gujarat, India. In addition to its India locations Kendle
currently operates offices in the Asia/Pacific region in Beijing, Hong Kong
and Shanghai, China; Singapore; and Sydney and Melbourne, Australia.
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical
research organization providing the full range of early- to late-stage
clinical development services for the world's biopharmaceutical industry. Our
focus is on innovative solutions that reduce cycle times for our customers and
accelerate the delivery of life-enhancing drugs to market for the benefit of
patients worldwide. As one of the fastest-growing global providers of Phase
I-IV services, we offer experience spanning 99 countries, along with
industry-leading patient access and retention capabilities and broad
therapeutic expertise, to meet our customers' clinical development challenges.
Kendle was recognized by FORTUNE magazine as one of the 100
fastest-growing companies in the United States for 2008. The company also has
been recognized as the "Top CRO to Work With" in the CenterWatch 2007 survey
of U.S. investigative sites and among the "Top CROs in Europe" in the 2008
survey of European sites.
Additional information and investor kits are available upon request from
Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the
Company's Web site at www.kendle.com .
Certain statements contained in this press release may be deemed to be
forward-looking statements under federal securities laws, and Kendle intends
that such forward-looking statements be subject to the safe-harbor created
thereby. Such forward-looking statements include, but are not limited to
Kendle's existing and planned growth and market penetration in the Asia
Pacific region, including India. Kendle cautions that these statements are
qualified by important factors that could cause actual results to differ
materially from those reflected by the forward-looking statements contained
herein. Such factors include (a) fluctuation in the exchange rate of the U.S.
dollar to other currencies; (b) the ability to set up and sustain growth
entities in the above described regions; (c) changes in the markets for the
company's service offerings; (d) changes in the market for customers'
products; and (e) other risks as detailed from time to time in Kendle's SEC
reports, including its Quarterly Reports on Form 10-Q, Current Reports on Form
8-K, and Annual Reports on Form 10-K.
SOURCE Kendle International Inc.